ISSN 1016-5169 | E-ISSN 1308-4488
pdf
New Myocardial Imaging Agent, Tc 99m MİBİ: Clinical Application, Advantages, and Limitations [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 1991; 19(2): 143-146

New Myocardial Imaging Agent, Tc 99m MİBİ: Clinical Application, Advantages, and Limitations

Deniz GÜZELSOY1, İsmail EREN1, Vedat SANSOY1, Afife BERKYÜREK1, Cem DEMİROĞLU1

The diagnostic value of a new myocardial imaging agent, technetium-99m hexaxis-2-methoxy-2- isobutyl isonitrile (Tc 99m MİBİ), in coronary artery disease (CAD) was investigated in 12 subjects. Advantages and limitations of MİBİ were reviewed. Exercise myocardial perfusion study with Tc 99m MİBİ and selective coronary arteriography were performed in all subjects. Tc 99m MİBİ was found to be negative in all 3 patients with normal coronary arteries. In 8 of 9 patients with angiographically documented CAD, perfusion defects were shown in one or more regions (sensitivity 88%). Liver uptake of Tc 99m MİBİ was considerable, and high background caused by high liver acitivity might interfere with image interpretation both qualitatively and quantitatively. We concluded that Tc 99m MİBİ provides a reliable method of assessment of CAD with a high sersitivity and, probably, a high specificity, but it has some disadvantages: high cost, high liver uptake and the requirement for a separate day resting injection.

Keywords: Coronary artery disease, myocardial perfusion scintigraphy with technetium-99m MIBI

How to cite this article
Deniz GÜZELSOY, İsmail EREN, Vedat SANSOY, Afife BERKYÜREK, Cem DEMİROĞLU. New Myocardial Imaging Agent, Tc 99m MİBİ: Clinical Application, Advantages, and Limitations. Turk Kardiyol Dern Ars. 1991; 19(2): 143-146
Manuscript Language: Turkish


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.